Dramatic price drops should allow countries to provide treatment for millions of people
On the eve of the World Hepatitis Summit in Sao Paolo, Médecins Sans Frontières (MSF) has announced that it has secured deals for generic hepatitis C medicines for as low as US$1.40 per day, or $120 per 12-week treatment course for the key medicines sofosbuvir and daclatasvir.
In the US, pharmaceutical corporation Gilead launched sofosbuvir at $1,000 per pill in 2013; Bristol-Myers Squibb (BMS) launched daclatasvir at $750 per pill in 2015. This led to the original price tag of $147,000 for a person’s 12-week combination treatment course. The corporations have also been charging exorbitant prices in many developing countries, paralysing the launch of national treatment programmes and causing treatment rationing in many countries around the world.